{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:33:32Z","timestamp":1787564012370,"version":"build-2736575974"},"reference-count":29,"publisher":"Bioscientifica","issue":"6","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The RET proto-oncogene, which encodes a receptor tyrosine kinase, is an important factor in the pathogenesis of medullary and papillary thyroid cancers. Selpercatinib and pralsetinib, both specific RET-kinase inhibitors, are the only FDA-approved drugs for treating RET-altered thyroid cancer. We wanted to evaluate the safety and efficacy of selpercatinib and pralsetinib in RET-altered thyroid cancers. We searched the PubMed, Embase, Cochrane, and Clinicaltrials.gov databases for randomized controlled trials and observational studies published up to March 30, 2024, and included those that reported any of the desired endpoints. The primary endpoints were 1-year progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Quantitative analyses were performed using the R programming language. We included four studies with 560 patients, 510 with RET-mutant and 50 with RET-fusion thyroid cancer. The 1-year PFS was 84% (95% CI, 79\u201388, I2 = 43%), ORR was 69% (95% CI, 65\u201373, I2 = 0) and DCR was 93% (95% CI, 89\u201396, I2 = 44%). Some important grade \u22653 adverse events were hypertension (16%; 95% CI, 11\u201322; I2 = 43%), diarrhea (3%; 95% CI, 2\u20135; I2 = 0), increased ALT (11%; 95% CI, 8\u201314; I2 = 0) and increased AST (6%; 95% CI, 4\u201310; I2 = 0). In conclusion, these findings suggest that selpercatinib and pralsetinib are efficacious and safe for use in patients with RET-altered thyroid cancer.<\/jats:p>","DOI":"10.1530\/erc-24-0219","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:07:34Z","timestamp":1746605254000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of RET-kinase inhibitors in RET-altered thyroid cancers: a systematic review and single-arm meta-analysis"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2668-3945","authenticated-orcid":true,"given":"Israt Jahan","family":"Riya","sequence":"first","affiliation":[{"name":"Dhaka Medical College and Hospital 1 , ,","place":["Dhaka, Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1577-7056","authenticated-orcid":true,"given":"Ifrat Jahan","family":"Piya","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital 1 , ,","place":["Dhaka, Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N","family":"Priantti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Federal University of Amazonas \u2013 UFAM 2 , , ,","place":["Manaus, Amazonas, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cha Len","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, University Health Network 3 , ,","place":["Ontario, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Barman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences New Delhi 4 , , ,","place":["New Delhi, Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almunthir","family":"Altobi","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, European University 5 , ,","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2026070905475499500_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"2026070905475499500_bib2","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070905475499500_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070905475499500_bib6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905475499500_bib7","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070905475499500_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes"},{"key":"2026070905475499500_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.1999.17.1.380","article-title":"RET proto-oncogene in the development of human cancer","volume":"17","author":"Eng","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026070905475499500_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-B043","article-title":"Abstract B043: preliminary results from a phase I\/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies","volume":"22","author":"Garralda","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026070905475499500_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070905475499500_bib12","volume-title":"Cochrane Handbook For Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"Higgins","year":"2024"},{"key":"2026070905475499500_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2005.15.531","article-title":"RET proto-oncogene: a review and update of genotype\u2013phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors","volume":"15","author":"Kouvaraki","year":"2005","journal-title":"Thyroid"},{"key":"2026070905475499500_bib14","doi-asserted-by":"crossref","first-page":"45784","DOI":"10.18632\/oncotarget.17412","article-title":"Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"2026070905475499500_bib15","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"2026070905475499500_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2013 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026070905475499500_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026070905475499500_bib18","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"2026070905475499500_bib19","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905475499500_bib21","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026070905475499500_bib22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026070905475499500_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"2026070905475499500_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"key":"2026070905475499500_bib3","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","author":"U.S. Department of Health and Human Services","year":"2009"},{"key":"2026070905475499500_bib4","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"2026070905475499500_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026070905475499500_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026070905475499500_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070905475499500_bib28","first-page":"3088","article-title":"Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas","volume":"80","author":"Zedenius","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905475499500_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119318","article-title":"Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study","volume":"14","author":"Zheng","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026070905475499500_bib30","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/6\/ERC-24-0219.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/6\/ERC-24-0219.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0219\/247061\/erc-24-0219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0219\/247061\/erc-24-0219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:48:01Z","timestamp":1783590481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/6\/e240219\/26066\/Efficacy-and-safety-of-RET-kinase-inhibitors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0219","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"e240219"}}